

Vadim Le Joncour
 Handledare för doktorandprogram, Titeln docent, forskardoktor
 Doctoral Programme in Biomedicine
 Centrum för neurovetenskap
 Fakultetens gemensamma (Medicinska fakulteten)
Adresstyp: Postadress.
 Finland
Adresstyp: Postadress.
 PL 63 (Haartmaninkatu 8)
 00014
 Finland
E-post: vadim.lejoncour@helsinki.fi
Telefon: +358294125579
Mobil: +358504486408



Meritförteckning

Personal details

Last, first name	Le Joncour, Vadim	Nationality:	French
Place of birth:	Rouen, France	Year of birth:	1985
ORCID:	0000-0001-8153-8563	ResearcherID:	X-6274-2019

Current affiliation: University of Helsinki, Helsinki Institute for Life Sciences (HiLIFE), Neuroscience Center and iCAN Flagship Digital Precision Cancer Medicine, Haartmaninkatu 8, 00290 Helsinki, Finland.

Degrees

2023	Title of Docent , Cancer Biology. Faculty of Medicine, University of Helsinki
2015	Doctor of Philosophy , <i>Implication of the urotensinergic system in neo-angiogenesis and invasion mechanisms of high-grade glioma</i> , Faculty of Science, University of Rouen, France
2010	Master of Science, Cellular and Molecular Neuroscience and Neuroendocrinology, Faculty of Science, University of Rouen, France
2008	Bachelor of Science, Life sciences – Animal Physiology, Neuroscience and Neuropsychology, Faculty of Science, University of Rouen, France

Current positions

2023 – 2028 **University Researcher** *Neuroplasticity and Neurotrophic Factors lab* (Research Director: Eero Castrén, M.D., Ph.D.).

Junior Team Leader *Neo[plastic] Brain Team*. HiLIFE, Neuroscience Center, University of Helsinki, Finland

2024 – 2026 **Co-Principal Investigator** iCAN-Plasticity: *Neuroplasticity in clinical cancer*. University of Helsinki, Finland.

Research output

2011 – 2024 **Total number of peer reviewed publications:** 27; conference proceedings: 11.

H-index: 16 (Web of Science) 16 (Google Scholar)

Number of times cited: 600 (Web of Science) 783 (Google Scholar)

2021 – 2024 Invention disclosure: UH ID No. 1121/2021 '*Navigator*: Peptide-based delivery of diagnostic tools and therapeutics to brain metastases'.

Research to Business (TUTL) 1051/31/2022. *Navigator* - novel tool for early brain metastases diagnostics. Helsingin Yliopisto.

Patent Pending on *Navigator*.

Previous work experience

2022 – 2023 iCAN Flagship Digital Precision Cancer Medicine, *iCAN-Brain: Deciphering the Dialogue between Astrocytes and Brain Tumors*. Faculty of Medicine, University of Helsinki, Finland

2019 – 2022 **Academy of Finland Post-doctoral Fellow** *The Mechanistic and Transcriptomic Signature of Brain Tumor Invasion*. CAN-PRO, University of Helsinki, Finland.

2015 – 2019 Post-doctoral researcher. *Research of novel molecular and cellular targets for glioblastoma and brain metastasis treatment*. Tumor Progression and Metastasis Lab (Lab. Head: Pirjo Laakkonen, Ph.D.), Research Programs Unit, Translational Cancer Biology, Faculty of Medicine, University of Helsinki, Finland

2013 – 2014 University lecturer & research assistant. Inserm U982/ANiVas lab. (Dir.: Hélène Castel, Ph.D.) University of Rouen, France

09.2010 – 06.14 Doctoral researcher, Inserm U982/ANiVas lab. (Dir.: Hélène Castel, Ph.D.) University of Rouen, France

Research funding and grants

Obtained as principal investigator

2025– 2028 Research Grant from the Finnish Cancer Society (EUR 181332) for *Modulators of neuronal plasticity for brain tumor cells reprogramming*

2024 Research Grant from the Finnish Cancer Society (EUR 50000) for *Modulators of neuronal plasticity for brain tumor cells reprogramming*

2023 Research Grant from the Magnus Ehrnrooth Foundation (EUR 5000) for *Neurodevelopmental features of the Neoplastic brain*

2022 Research Grant from the Magnus Ehrnrooth Foundation (EUR 5000) for *Mapping invasive glioblastoma cells reprogramming into neuron-like cells*

Maupertuis Programme (EUR 1200) collaborative grant for the scientific cooperation between the Seano (Institut Curie, FR) and Le Joncour (Helsinki University, FIN) Labs

2021 Research Grant from the Magnus Ehrnrooth Foundation (EUR 8000) for *Revealing the invasive brain tumor cell identity*

Personal grant from K. Albin Johansson stiftelse (EUR 5000) for *Mapping brain tumor cells' reprogramming and invasion*

2020 Research Grant from the Magnus Ehrnrooth foundation (EUR 5000) for *Cationic amphiphilic molecules to treat invasive brain tumors*

2019 – 2022 Academy of Finland Postdoc fellowship *Investigating the transcriptomic and mechanistic signature of invasive gliomas*, University of Helsinki, Finland (EUR 290,000)

2019 Personal grant from K. Albin Johansson stiftelse (EUR 5000) for *Investigating the transcriptomic and mechanistic signature of invasive gliomas*

Awards and honors and academic merits

2022 **Best presentation** price at the Scandinavian Society of Neuro-Oncology (200+ participants). Helsinki, Finland <https://bit.ly/3LYTm8i>

Invited talks Université de Nantes, France (06.2021), Cardiff University, UK (03.2022), 10x Genomics, Helsinki (05.2022), Institut Curie, Paris (06.2022) <https://bit.ly/3cy8j5r>, Normandie Universités, France (06.2022), HiLIFE, Neuroscience Center (04.2023), Lundbeck Foundation (02.2024).

2020 & 2022 Organizer of the 1st & 3rd FiBTRA Virtual seminar (27.10.2022) <https://bit.ly/3CFhtY2>

2021 – 2022 Senior evaluator for the EuroTechPostdoc2 2021 & 2022 calls, Marie Skłodowska-Curie fellowship programme

2019 Award at the Finnish Brain Tumor Research Association (FiBTRA) (80+ participants). Helsinki, Finland.

2015 & 2019 Co-organizer of the FiBTRA annual meetings (Helsinki, Finland, 80+ participants)

2016 – Review of 30+ research and 3 review articles

2015 – Board, Finnish Brain Tumor Research Association http://fibtra.org/fibtra_board.html

Anställning

Handledare för doktorandprogram

Doctoral Programme in Biomedicine
Helsingfors universitet
Finland
1 jan. 2015 → present

forskardoktor

Centrum för neurovetenskap
Helsingfors universitet
Finland
1 maj 2023 → present

Titeln docent

Fakultetens gemensamma (Medicinska fakulteten)
Helsingfors universitet
Finland
24 mars 2023 → present

Forskningsoutput

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

Pourjamal, N., Le Joncour, V., Vereb, G., Honkamäki, C., Isola, J., Leyton, J. V., Laakkonen, P., Joensuu, H. & Barok, M., mars 2025, I: Translational oncology. 53, 9 s., 102284.

Supersoft Sponge-like Cryogel As an Implant to Treat Glioblastoma

Wang, Y., Le Joncour, V., Laakkonen, P. & Newland, B., 15 okt. 2024, I: Neuro-Oncology. 26, Supplement 7 , s. vii16 1 s.

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

Pourjamal, N., Yazdi, N., Halme, A., Le Joncour, V., Laakkonen, P., Saharinen, P., Joensuu, H. & Barok, M., 2024, I: Clinical and Experimental Metastasis. 41, s. 91–10 12 s.

Heparin-Derived Theranostic Nanoprobes Overcome the Blood-Brain Barrier and Target Glioma in Murine Model

Samanta, S., Le Joncour, V., Wegrzyniak, O., Rangasami, V. K., Ali-Loytty, H., Hong, T., Selvaraju, R. K., Aberg, O., Hilborn, J., Laakkonen, P., Varghese, O. P., Eriksson, O., Cabral, H. & Oommen, O. P., juni 2022, I: Advanced Therapeutics. 5, 6, 17 s., 2200001.

Bivalent EGFR-Targeting DARPIn-MMAE Conjugates

Karsten, L., Janson, N., Le Joncour, V., Alam, S., Müller, B., Tanjore Ramanathan, J., Laakkonen, P., Sewald, N. & Mueller, K. M., mars 2022, I: International Journal of Molecular Sciences. 23, 5, 26 s., 2468.

Peptidotriazolamers Inhibit A beta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model

Tonali, N., Hericks, L., Schroeder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., Laakkonen, P., Marion, A., Onger, S., Dodero, V. I. & Sewald, N., juni 2021, I: ChemPlusChem. 86, 6, s. 840-851 12 s.

Redox responsive Pluronic micelle mediated delivery of functional siRNA: a modular nano-assembly for targeted delivery

Kadekar, S., Nawale, G., Rangasami, V., Le Joncour, V., Laakkonen, P., Hilborn, J., Varghese, O. & Oommen, O., juni 2021, I: Biomaterials Science. 9, 11, s. 3939-3944 6 s.

Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions

Prabhakar, N., Merisaari, J., Le Joncour, V., Peurla, M., Sen Karaman, D., Casals, E., Laakkonen, P., Westermarck, J. & Rosenholm, J. M., 27 maj 2021, I: Cancers. 13, 11, 19 s., 2631.

CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity

Filppu, P., Ramanathan, J. T., Granberg, K. J., Gucciardo, E., Haapasalo, H., Lehti, K., Nykter, M., Le Joncour, V. & Laakkonen, P., 10 maj 2021, I: JCI INSIGHT. 6, 9, 21 s., 141486.

Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain

Ramanathan, J. T., Lehtipuro, S., Sihto, H., Tovari, J., Reiniger, L., Teglas, V., Moldvay, J., Nykter, M., Haapasalo, H., Le Joncour, V. & Laakkonen, P., juni 2020, I: Journal of Cellular and Molecular Medicine. 24, 12, s. 6916-6927 12 s.

Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls

Eriksson, J., Le Joncour, V., Jahkola, T., Juteau, S., Laakkonen, P., Saksela, O. & Hölttä, E., apr. 2020, I: Molecular oncology. 14, 4, s. 742-762 21 s.

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Barok, M., Le Joncour, V., Martins, A., Isola, J., Salmikangas, M., Laakkonen, P. & Joensuu, H., 2020, I: Cancer Letters. 473, s. 156-163 8 s.

Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma

Merisaari, J., Denisova, O., Doroszko, M., Le Joncour, V., Johansson, P., Leenders, W. P. J., Kastrinsky, D. B., Zaware, N., Narla, G., Laakkonen, P., Nelander, S., Ohlmeyer, M. & Westermarck, J., 2020, I: Brain communications. 2, 1, 12 s., 02.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine

Le Joncour, V., Martins, A., Puhka, M., Isola, J., Salmikangas, M., Laakkonen, P., Joensuu, H. & Barok, M., okt. 2019, I: Molecular Cancer Therapeutics. 18, 10, s. 1721-1730 10 s.

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization

Le Joncour, V., Filppu, P., Hyvönen, M., Holopainen, M., Turunen, S. P., Sihto, H., Burghardt, I., Joensuu, H., Tynnenen, O., Jääskeläinen, J., Weller, M., Lehti, K., Käkelä, R. & Laakkonen, P., juni 2019, I: EMBO molecular medicine. 11, 6, 21 s., 9034.

Octreotide Conjugates for Tumor Targeting and Imaging

Figueras, E., Martins, A., Borbely, A., Le Joncour, V., Cordella, P., Perego, R., Modena, D., Pagani, P., Esposito, S., Auciello, G., Frese, M., Gallinari, P., Laakkonen, P., Steinkuhler, C. & Sewald, N., maj 2019, I: Pharmaceutics. 11, 5, 14 s., 220.

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Le Joncour, V., Karaman, S. & Laakkonen, P. M., 16 apr. 2019, I: Journal of Visualized Experiments. 146, 12 s., 59384.

Seek & Destroy, use of targeting peptides for cancer detection and drug delivery

Le Joncour, V. & Laakkonen, P., 1 juni 2018, I: Bioorganic & Medicinal Chemistry. 26, 10, s. 2797-2806 10 s.

Targeting peptides, a Swiss-army knife against cancer

Le Joncour, V. J. M. & Laakkonen, P., 2018, *Amino Acids, Peptides and Proteins*. Ryadnov, M. & Hudecz, F. (red.). Royal Society of Chemistry, Vol. 42. s. 281-320 40 s.

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression

Eriksson, J., Le Joncour, V., Nummela, P., Jahkola, T., Virolainen, S., Laakkonen, P., Saksela, O. & Hölttä, E., 22 mars 2016, I: Oncotarget. 7, 12, s. 15065-15092 28 s.

Aktiviteter

Finnish Brain Tumor Research Association Annual Meeting: FiBTRA 2019

Laakkonen, P. (Medlem i organisationskommitté), Le Joncour, V. (Medlem i organisationskommitté) & Filppu, P. (Medlem i organisationskommitté)
31 okt. 2019 → 1 nov. 2019

Oral presentation to FiBTRA 2017

Le Joncour, V. (!!Speaker)
27 okt. 2017

Finnish Brain Tumor Research Association Annual Meeting

Le Joncour, V. (Medlem i organisationskommitté), Laakkonen, P. M. (Medlem i organisationskommitté), Filppu, P. I. (Närvarande), Tanjore Ramanathan, J. (Närvarande), Ayo, A. O. (Närvarande), Ylä-Herttua, S. (Talare: Inledningsanförande (keynote)) & Westermarck, J. (Medlem i organisationskommitté)
1 nov. 2016 → 2 nov. 2016

Presentation to the Magic Bullet Network Meeting

Le Joncour, V. (!!Speaker)
19 juli 2016

Priser

FiBTRA 2019 selected talk

Le Joncour, V. (!!Recipient), 1 nov. 2019

K. Albin Johansson foundation

Le Joncour, V. (!!Recipient), 11 dec. 2019

Press/media

Cover of the EMBO Molecular Medicine journal

Le Joncour, V.

07/06/2019

1 objekt av Mediabevakning

Exploiting a Chink in the Armor of Brain Tumor Cells

Laakkonen, P. & Le Joncour, V.

13/05/2019

1 objekt av Mediabevakning

Researchers discover the Achilles' heel of an aggressive brain cancer

Sihto, H., Joensuu, H., Laakkonen, P. & Le Joncour, V.

10/05/2019 → 13/05/2019

8 objekt av Mediabevakning

-UNIVERSITY OF HELSINKI: Researchers discover the Achilles' heel of an aggressive brain cancer - could antihistamine be a potential aid in defeating cancerous cells?

Sihto, H., Joensuu, H., Laakkonen, P. & Le Joncour, V.

13/05/2019

1 objekt av Mediabevakning